Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 125

1.

α7 nicotinic receptor agonists reduce levodopa-induced dyskinesias with severe nigrostriatal damage.

Zhang D, McGregor M, Bordia T, Perez XA, McIntosh JM, Decker MW, Quik M.

Mov Disord. 2015 Dec;30(14):1901-1911. doi: 10.1002/mds.26453. Epub 2015 Nov 17.

2.

The α7 nicotinic receptor agonist ABT-107 protects against nigrostriatal damage in rats with unilateral 6-hydroxydopamine lesions.

Bordia T, McGregor M, Papke RL, Decker MW, McIntosh JM, Quik M.

Exp Neurol. 2015 Jan;263:277-84. doi: 10.1016/j.expneurol.2014.09.015. Epub 2014 Sep 28.

3.

The α7 nicotinic receptor agonist ABT-107 decreases L-Dopa-induced dyskinesias in parkinsonian monkeys.

Zhang D, McGregor M, Decker MW, Quik M.

J Pharmacol Exp Ther. 2014 Oct;351(1):25-32. doi: 10.1124/jpet.114.216283. Epub 2014 Jul 17.

4.

ABT-089 and ABT-894 reduce levodopa-induced dyskinesias in a monkey model of Parkinson's disease.

Zhang D, Bordia T, McGregor M, McIntosh JM, Decker MW, Quik M.

Mov Disord. 2014 Apr;29(4):508-17. doi: 10.1002/mds.25817. Epub 2014 Feb 11.

5.

α7 Nicotinic receptor agonist enhances cognition in aged 3xTg-AD mice with robust plaques and tangles.

Medeiros R, Castello NA, Cheng D, Kitazawa M, Baglietto-Vargas D, Green KN, Esbenshade TA, Bitner RS, Decker MW, LaFerla FM.

Am J Pathol. 2014 Feb;184(2):520-9. doi: 10.1016/j.ajpath.2013.10.010. Epub 2013 Nov 19.

PMID:
24269557
6.

Assessing carrageenan-induced locomotor activity impairment in rats: comparison with evoked endpoint of acute inflammatory pain.

Zhu CZ, Mills CD, Hsieh GC, Zhong C, Mikusa J, Lewis LG, Gauvin D, Lee CH, Decker MW, Bannon AW, Rueter LE, Joshi SK.

Eur J Pain. 2012 Jul;16(6):816-26. doi: 10.1002/j.1532-2149.2011.00099.x. Epub 2012 Jan 19.

PMID:
22337256
7.

Neurobiology of nAChRs and cognition: a mini review of Dr. Jerry J. Buccafusco's contributions over a 25 year career.

Terry AV Jr, Decker MW.

Biochem Pharmacol. 2011 Oct 15;82(8):883-90. doi: 10.1016/j.bcp.2011.06.010. Epub 2011 Jun 12. Review.

8.

Potentiation of analgesic efficacy but not side effects: co-administration of an α4β2 neuronal nicotinic acetylcholine receptor agonist and its positive allosteric modulator in experimental models of pain in rats.

Zhu CZ, Chin CL, Rustay NR, Zhong C, Mikusa J, Chandran P, Salyers A, Gomez E, Simler G, Lewis LG, Gauvin D, Baker S, Pai M, Tovcimak A, Brown J, Komater V, Fox GB, Decker MW, Jacobson PB, Gopalakrishnan M, Lee CH, Honore P.

Biochem Pharmacol. 2011 Oct 15;82(8):967-76. doi: 10.1016/j.bcp.2011.05.007. Epub 2011 May 17.

PMID:
21620806
9.

Cognition Models and Drug Discovery.

Decker MW.

In: Levin ED, Buccafusco JJ, editors. Animal Models of Cognitive Impairment. Boca Raton (FL): CRC Press/Taylor & Francis; 2006. Chapter 16.

10.

Pharmacokinetic modeling and [¹²³]5-IA-85380 single photon emission computed tomography imaging in baboons: optimization of dosing regimen for ABT-089.

Chin CL, Carr RA, Llano DA, Barret O, Xu H, Batis J, Koren AO, Seibyl JP, Marsh KC, Tamagnan G, Decker MW, Day M, Fox GB.

J Pharmacol Exp Ther. 2011 Mar;336(3):716-23. doi: 10.1124/jpet.110.173609. Epub 2010 Dec 20.

PMID:
21172907
11.

Antinociceptive effects of histamine H3 receptor antagonist in the preclinical models of pain in rats and the involvement of central noradrenergic systems.

Hsieh GC, Honore P, Pai M, Wensink EJ, Chandran P, Salyers AK, Wetter JM, Zhao C, Liu H, Decker MW, Esbenshade TA, Cowart MD, Brioni JD.

Brain Res. 2010 Oct 1;1354:74-84. doi: 10.1016/j.brainres.2010.07.083. Epub 2010 Aug 1.

PMID:
20682302
12.

In vivo pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107: preclinical considerations in Alzheimer's disease.

Bitner RS, Bunnelle WH, Decker MW, Drescher KU, Kohlhaas KL, Markosyan S, Marsh KC, Nikkel AL, Browman K, Radek R, Anderson DJ, Buccafusco J, Gopalakrishnan M.

J Pharmacol Exp Ther. 2010 Sep 1;334(3):875-86. doi: 10.1124/jpet.110.167213. Epub 2010 May 26.

PMID:
20504913
13.

Prefrontal beta2 subunit-containing and alpha7 nicotinic acetylcholine receptors differentially control glutamatergic and cholinergic signaling.

Parikh V, Ji J, Decker MW, Sarter M.

J Neurosci. 2010 Mar 3;30(9):3518-30. doi: 10.1523/JNEUROSCI.5712-09.2010.

14.

ABT-594 improves performance in the 5-choice serial reaction time task under conditions of increased difficulty, sub-chronic dosing, and in poorly-performing subjects.

Mohler EG, Franklin SR, Rueter LE, Fox GB, Decker MW, Browman KE.

Pharmacol Biochem Behav. 2010 Apr;95(2):146-57. doi: 10.1016/j.pbb.2009.12.019. Epub 2010 Jan 11.

PMID:
20064548
15.

Mice expressing the Swedish APP mutation on a 129 genetic background demonstrate consistent behavioral deficits and pathological markers of Alzheimer's disease.

Rustay NR, Cronin EA, Curzon P, Markosyan S, Bitner RS, Ellis TA, Waring JF, Decker MW, Rueter LE, Browman KE.

Brain Res. 2010 Jan 22;1311:136-47. doi: 10.1016/j.brainres.2009.11.040. Epub 2009 Nov 26.

PMID:
19944081
16.

Comparison of mechanical allodynia and the affective component of inflammatory pain in rats.

Boyce-Rustay JM, Zhong C, Kohnken R, Baker SJ, Simler GH, Wensink EJ, Decker MW, Honore P.

Neuropharmacology. 2010 Feb;58(2):537-43. doi: 10.1016/j.neuropharm.2009.08.008. Epub 2009 Aug 22.

PMID:
19703478
17.

Pharmacological modulation of movement-evoked pain in a rat model of osteoarthritis.

Chandran P, Pai M, Blomme EA, Hsieh GC, Decker MW, Honore P.

Eur J Pharmacol. 2009 Jun 24;613(1-3):39-45. doi: 10.1016/j.ejphar.2009.04.009. Epub 2009 Apr 16.

PMID:
19376109
18.

Peripheral and central sites of action for the non-selective cannabinoid agonist WIN 55,212-2 in a rat model of post-operative pain.

Zhu CZ, Mikusa JP, Fan Y, Hollingsworth PR, Pai M, Chandran P, Daza AV, Yao BB, Dart MJ, Meyer MD, Decker MW, Hsieh GC, Honore P.

Br J Pharmacol. 2009 Jun;157(4):645-55. doi: 10.1111/j.1476-5381.2009.00184.x. Epub 2009 Apr 3.

19.

Behavioral profile of P2X7 receptor knockout mice in animal models of depression and anxiety: relevance for neuropsychiatric disorders.

Basso AM, Bratcher NA, Harris RR, Jarvis MF, Decker MW, Rueter LE.

Behav Brain Res. 2009 Mar 2;198(1):83-90. doi: 10.1016/j.bbr.2008.10.018. Epub 2008 Oct 18.

PMID:
18996151
20.

The potential of neuronal nicotinic acetylcholine receptor agonists for treating CNS conditions.

Decker MW, Gopalakrishnan M, Meyer MD.

Expert Opin Drug Discov. 2008 Sep;3(9):1027-40. doi: 10.1517/17460441.3.9.1027.

PMID:
23506178
21.

Glutamatergic contributions to nicotinic acetylcholine receptor agonist-evoked cholinergic transients in the prefrontal cortex.

Parikh V, Man K, Decker MW, Sarter M.

J Neurosci. 2008 Apr 2;28(14):3769-80. doi: 10.1523/JNEUROSCI.5251-07.2008.

22.

Broad-spectrum efficacy across cognitive domains by alpha7 nicotinic acetylcholine receptor agonism correlates with activation of ERK1/2 and CREB phosphorylation pathways.

Bitner RS, Bunnelle WH, Anderson DJ, Briggs CA, Buccafusco J, Curzon P, Decker MW, Frost JM, Gronlien JH, Gubbins E, Li J, Malysz J, Markosyan S, Marsh K, Meyer MD, Nikkel AL, Radek RJ, Robb HM, Timmermann D, Sullivan JP, Gopalakrishnan M.

J Neurosci. 2007 Sep 26;27(39):10578-87.

23.

Profile of nicotinic acetylcholine receptor agonists ABT-594 and A-582941, with differential subtype selectivity, on delayed matching accuracy by young monkeys.

Buccafusco JJ, Terry AV Jr, Decker MW, Gopalakrishnan M.

Biochem Pharmacol. 2007 Oct 15;74(8):1202-11. Epub 2007 Jul 14.

PMID:
17706609
24.

Neuronal nicotinic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: focus on cognition.

Wilens TE, Decker MW.

Biochem Pharmacol. 2007 Oct 15;74(8):1212-23. Epub 2007 Jul 7. Review.

25.

Effects of antipsychotics and selective D3 antagonists on PPI deficits induced by PD 128907 and apomorphine.

Zhang M, Ballard ME, Unger LV, Haupt A, Gross G, Decker MW, Drescher KU, Rueter LE.

Behav Brain Res. 2007 Aug 22;182(1):1-11. Epub 2007 May 1.

PMID:
17570538
26.

Differential effects of ciproxifan and nicotine on impulsivity and attention measures in the 5-choice serial reaction time test.

Day M, Pan JB, Buckley MJ, Cronin E, Hollingsworth PR, Hirst WD, Navarra R, Sullivan JP, Decker MW, Fox GB.

Biochem Pharmacol. 2007 Apr 15;73(8):1123-34. Epub 2006 Dec 9.

PMID:
17214974
27.

The drug-induced helplessness test: an animal assay for assessing behavioral despair in response to neuroleptic treatment.

Ballard ME, Basso AM, Gallagher KB, Browman KE, Fox GB, Drescher KU, Gross G, Decker MW, Rueter LE, Zhang M.

Psychopharmacology (Berl). 2007 Jan;190(1):1-11. Epub 2006 Nov 9.

PMID:
17093979
28.

Antisense knockdown of the rat alpha7 nicotinic acetylcholine receptor produces spatial memory impairment.

Curzon P, Anderson DJ, Nikkel AL, Fox GB, Gopalakrishnan M, Decker MW, Bitner RS.

Neurosci Lett. 2006 Dec 13;410(1):15-9. Epub 2006 Oct 20.

PMID:
17055644
29.

Blockade of mGluR1 receptor results in analgesia and disruption of motor and cognitive performances: effects of A-841720, a novel non-competitive mGluR1 receptor antagonist.

El-Kouhen O, Lehto SG, Pan JB, Chang R, Baker SJ, Zhong C, Hollingsworth PR, Mikusa JP, Cronin EA, Chu KL, McGaraughty SP, Uchic ME, Miller LN, Rodell NM, Patel M, Bhatia P, Mezler M, Kolasa T, Zheng GZ, Fox GB, Stewart AO, Decker MW, Moreland RB, Brioni JD, Honore P.

Br J Pharmacol. 2006 Nov;149(6):761-74. Epub 2006 Oct 3.

30.

The analgesic potential of compounds acting at acetylcholine receptors.

Decker MW.

Curr Opin Anaesthesiol. 1999 Oct;12(5):597-601.

PMID:
17016255
31.

TRPV1 receptors in the CNS play a key role in broad-spectrum analgesia of TRPV1 antagonists.

Cui M, Honore P, Zhong C, Gauvin D, Mikusa J, Hernandez G, Chandran P, Gomtsyan A, Brown B, Bayburt EK, Marsh K, Bianchi B, McDonald H, Niforatos W, Neelands TR, Moreland RB, Decker MW, Lee CH, Sullivan JP, Faltynek CR.

J Neurosci. 2006 Sep 13;26(37):9385-93.

32.

Comparison of antinociceptive actions of standard analgesics in attenuating capsaicin and nerve-injury-induced mechanical hypersensitivity.

Joshi SK, Hernandez G, Mikusa JP, Zhu CZ, Zhong C, Salyers A, Wismer CT, Chandran P, Decker MW, Honore P.

Neuroscience. 2006 Dec 1;143(2):587-96. Epub 2006 Sep 8.

PMID:
16962719
33.

Alpha4beta2 nicotinic receptor stimulation contributes to the effects of nicotine in the DBA/2 mouse model of sensory gating.

Radek RJ, Miner HM, Bratcher NA, Decker MW, Gopalakrishnan M, Bitner RS.

Psychopharmacology (Berl). 2006 Jul;187(1):47-55. Epub 2006 May 6.

PMID:
16767415
34.

Evidence for tolerance following repeated dosing in rats with ciproxifan, but not with A-304121.

Pan JB, Yao BB, Miller TR, Kroeger PE, Bennani YL, Komater VA, Esbenshade TA, Hancock AA, Decker MW, Fox GB.

Life Sci. 2006 Aug 29;79(14):1366-79. Epub 2006 Apr 26.

PMID:
16730751
35.

Dissociation between post-surgical pain behaviors and spinal Fos-like immunoreactivity in the rat.

Zhu CZ, Nikkel AL, Martino B, Bitner RS, Decker MW, Honore P.

Eur J Pharmacol. 2006 Feb 15;531(1-3):108-17. Epub 2006 Jan 24.

PMID:
16438960
36.

Effect of dopamine D3 antagonists on PPI in DBA/2J mice or PPI deficit induced by neonatal ventral hippocampal lesions in rats.

Zhang M, Ballard ME, Kohlhaas KL, Browman KE, Jongen-Rêlo AL, Unger LV, Fox GB, Gross G, Decker MW, Drescher KU, Rueter LE.

Neuropsychopharmacology. 2006 Jul;31(7):1382-92. Epub 2005 Dec 14.

37.

Dopamine D4 receptor signaling in the rat paraventricular hypothalamic nucleus: Evidence of natural coupling involving immediate early gene induction and mitogen activated protein kinase phosphorylation.

Bitner RS, Nikkel AL, Otte S, Martino B, Barlow EH, Bhatia P, Stewart AO, Brioni JD, Decker MW, Moreland RB.

Neuropharmacology. 2006 Apr;50(5):521-31. Epub 2005 Dec 1.

PMID:
16324724
38.

Interleukin-1alphabeta gene-deficient mice show reduced nociceptive sensitivity in models of inflammatory and neuropathic pain but not post-operative pain.

Honore P, Wade CL, Zhong C, Harris RR, Wu C, Ghayur T, Iwakura Y, Decker MW, Faltynek C, Sullivan J, Jarvis MF.

Behav Brain Res. 2006 Feb 28;167(2):355-64. Epub 2005 Oct 26.

PMID:
16256210
39.

A-412997, a selective dopamine D4 agonist, improves cognitive performance in rats.

Browman KE, Curzon P, Pan JB, Molesky AL, Komater VA, Decker MW, Brioni JD, Moreland RB, Fox GB.

Pharmacol Biochem Behav. 2005 Sep;82(1):148-55. Epub 2005 Sep 8.

PMID:
16154186
40.

Preclinical profiling and safety studies of ABT-769: a compound with potential for broad-spectrum antiepileptic activity.

Giardina WJ, Dart MJ, Harris RR, Bitner RS, Radek RJ, Fox GB, Chemburkar SR, Marsh KC, Waring JF, Hui JY, Chen J, Curzon P, Grayson GK, Komater VA, Ku Y, Lockwood M, Miner HM, Nikkel AL, Pan JB, Pu YM, Wang L, Bennani Y, Durmuller N, Jolly R, Roux S, Sullivan JP, Decker MW.

Epilepsia. 2005 Sep;46(9):1349-61.

41.

Selective H3 receptor (H3R) blockade: broad efficacy in cognition and schizophrenia.

Fox GB, Esbenshade TA, Pan JB, Browman KE, Zhang M, Ballard ME, Radek RJ, Miner H, Bitner RS, Krueger KM, Yao BB, Faghih R, Rueter LE, Komater VA, Drescher KU, Buckley MJ, Sullivan JP, Cowart MD, Decker MW, Hancock AA.

Inflamm Res. 2005 Apr;54 Suppl 1:S23-4. No abstract available.

PMID:
15928819
42.

Lack of cataleptogenic potentiation with non-imidazole H3 receptor antagonists reveals potential drug-drug interactions between imidazole-based H3 receptor antagonists and antipsychotic drugs.

Zhang M, Ballard ME, Pan L, Roberts S, Faghih R, Cowart M, Esbenshade TA, Fox GB, Decker MW, Hancock AA, Rueter LE.

Brain Res. 2005 May 31;1045(1-2):142-9. Epub 2005 Apr 20.

PMID:
15910772
43.

Effects of histamine H3 receptor antagonists in two models of spatial learning.

Komater VA, Buckley MJ, Browman KE, Pan JB, Hancock AA, Decker MW, Fox GB.

Behav Brain Res. 2005 Apr 30;159(2):295-300. Epub 2004 Dec 10.

PMID:
15817192
44.

Role of central and peripheral mGluR5 receptors in post-operative pain in rats.

Zhu CZ, Hsieh G, Ei-Kouhen O, Wilson SG, Mikusa JP, Hollingsworth PR, Chang R, Moreland RB, Brioni J, Decker MW, Honore P.

Pain. 2005 Mar;114(1-2):195-202. Epub 2005 Jan 21.

PMID:
15733645
45.

ABT-594 (a nicotinic acetylcholine agonist): anti-allodynia in a rat chemotherapy-induced pain model.

Lynch JJ 3rd, Wade CL, Mikusa JP, Decker MW, Honore P.

Eur J Pharmacol. 2005 Feb 10;509(1):43-8.

PMID:
15713428
46.

Antidepressant-like effect of D(2/3) receptor-, but not D(4) receptor-activation in the rat forced swim test.

Basso AM, Gallagher KB, Bratcher NA, Brioni JD, Moreland RB, Hsieh GC, Drescher K, Fox GB, Decker MW, Rueter LE.

Neuropsychopharmacology. 2005 Jul;30(7):1257-68.

47.

Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 receptor antagonist.

Fox GB, Esbenshade TA, Pan JB, Radek RJ, Krueger KM, Yao BB, Browman KE, Buckley MJ, Ballard ME, Komater VA, Miner H, Zhang M, Faghih R, Rueter LE, Bitner RS, Drescher KU, Wetter J, Marsh K, Lemaire M, Porsolt RD, Bennani YL, Sullivan JP, Cowart MD, Decker MW, Hancock AA.

J Pharmacol Exp Ther. 2005 Apr;313(1):176-90. Epub 2004 Dec 17.

PMID:
15608077
48.

Assessing the role of metabotropic glutamate receptor 5 in multiple nociceptive modalities.

Zhu CZ, Wilson SG, Mikusa JP, Wismer CT, Gauvin DM, Lynch JJ 3rd, Wade CL, Decker MW, Honore P.

Eur J Pharmacol. 2004 Dec 15;506(2):107-18.

PMID:
15588730
49.
50.

The adenosine kinase inhibitor ABT-702 augments EEG slow waves in rats.

Radek RJ, Decker MW, Jarvis MF.

Brain Res. 2004 Nov 5;1026(1):74-83.

PMID:
15476699

Supplemental Content

Loading ...
Support Center